BBC3 and neoplasm: While the WT tumour growth was suppressed by 70%‐80% upon gilteritinib treatment (Figure 7A), PUMA‐KO tumours were significantly less sensitive to the treatment (Figure 7A), indicating that the antitumour activity of gilteritinib is nullified in the absence of PUMA.